Callidus Biopharma
Drug discovery company developing enzyme replacement therapies for lysosomal storage disorders.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD25—38m (Dealroom.co estimates May 2013.)
Doylestown Township Pennsylvania (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.6m | Seed | |
N/A | $4.6m | Series A | |
N/A | Acquisition | ||
Total Funding | CAD8.5m |
Related Content
Recent News about Callidus Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.